Evidence map›Paper›PMID 21362119›Full record

ArticleTraffic (Copenhagen, Denmark)2011

Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions.

Maria K E Blixt, Stephen J Royle

Open access · bronzeAbstract read
In one paragraph

Article in Traffic (Copenhagen, Denmark), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Maria K E BlixtPhysiological Laboratory and Cancer Research UK Centre, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK.
Stephen J Royle
Cancer Research UK · GBUniversity of Liverpool · GB

Funding

Cancer Research UK A8722Cancer Research UK C25425/A8722
6 · The paper itself

Abstract

Clathrin is a protein expressed ubiquitously that has important functions in membrane trafficking and mitosis. Two different gene fusions involving clathrin heavy chain (CHC) have been described in human cancers. These involve either anaplastic lymphoma kinase (ALK) or transcription factor binding to IGHM enhancer 3 (TFE3) and raise the possibility that altered clathrin function in cells expressing the fusion proteins could contribute to oncogenesis. In the present study, we tested the functions of CHC-ALK and CHC-TFE3 in endocytosis and mitosis. CHC-ALK is comparable to full-length CHC in both functions indicating that malignant transformation in cells expressing CHC-ALK is not because of any change in clathrin function. CHC-TFE3 is not functional in endocytosis, but can substitute for CHC in mitosis. CHC-TFE3 causes prolonged interphase that is attributed to the TFE3 portion of the protein. We also describe how CHC-TFE3 is a dimer. This suggests that clathrin's proposed role in intermicrotubule bridging can be fulfilled not only by trimers but also by dimers. Finally, this study shows that the membrane trafficking and mitotic functions of clathrin are independent and separable.

Indexed as

Gene FusionAnaplastic Lymphoma KinaseAnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell CycleClathrin Heavy ChainsHEK293 CellsHumansMicrotubulesNeoplasmsProtein MultimerizationReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsClathrin Heavy ChainsReceptor Protein-Tyrosine KinasesTFE3 protein, human

Identifiers

PMID21362119
PMCPMC3362863
OpenAlexW2081678833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.